New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer
Mené aux Etats-Unis et en Europe sur 105 patients atteints d’un cancer du poumon à petites cellules, cet essai panier de phase II évalue l’efficacité, du point de vue du taux de réponse globale, et la toxicité de la lurbinectedine (un inhibiteur de la transcription) en traitement de deuxième ligne après l’échec d’une chimiothérapie à base de sels de platine
Outstanding progress has been made in the past 15 years for the treatment of patients with non-small-cell lung cancer, improving survival and quality of life. However, the outlook for patients with small-cell lung cancer (SCLC) differs, and therapeutic advances in this field are lagging, resulting in a notable survival gap between the two disease subtypes.
The Lancet Oncology , commentaire, 2019